Allen Ho, MD, FACS, FASRS, will make a presentation at the meeting, to be held virtually on February 3.
Lineage Cell Therapeutics Inc announced that results showing retinal structure improvements with RG6501 (OpRegen) from a Phase 1/2a clinical study (NCT02286089) in geographic atrophy (GA) secondary to advanced age-related macular degeneration (AMD) will be presented at the 2024 Angiogenesis, Exudation, and Degeneration Meeting.
According to a news release,1 the meeting will be held virtually February 3 and is sponsored by the University of Miami Health System Bascom Palmer Eye Institite.
Allen Ho, MD, FACS, FASRS, will present “Retinal Structure Improvements with OpRegen RPE Cell Therapy in a Phase I/IIa Study in Geographic Atrophy." He is co-director, Wills Eye Retina Service and Director, Retina Research, Wills Eye Hospital on behalf of Roche and Genentech, a member of the Roche Group.
According to the news release, RG6501 (OpRegen) is a suspension of human allogeneic retinal pigment epithelial (RPE) cells currently in development for the treatment of GA secondary to AMD. OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function. It is being developed under an exclusive global partnership between Lineage, and Roche and Genentech, a member of the Roche Group, and is currently being evaluated in a Phase 2a clinical study in patients with GA secondary to AMD (NCT05626114).1
According to the news release noted the 21st Annual Angiogenesis meeting, titled Angiogenesis, Exudation, and Degeneration 2024, will be held virtually on February 3.
re an exceptional group of basic scientists, clinicians, and healthcare experts, all focused on understanding and treating neovascular, exudative, and degenerative diseases of the eye.
Organizers noted in the news release the program will highlight the pharmacotherapies now in development and clinical practice for the management of neovascular AMD, macular edema, diabetic retinopathy, retinopathy of prematurity, and inherited retinal degenerations with a special emphasis on the present and future financial impact of these drugs on clinical practices and Medicare.1